about
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trialREpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stemTRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.Gene expression profiling in bladder cancer identifies potential therapeutic targetsInvestigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol.Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial.Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.Transplantation of discarded livers following viability testing with normothermic machine perfusion
P50
Q28661700-143D5D9E-3BB5-45DE-83D2-1EE00C1F1312Q35203746-51253827-C668-4294-8992-A8D6B1FEEB81Q36081868-CBB54BBF-AC8E-4EAE-93BE-63EE755EADE9Q36465496-2C73308C-5149-4D07-B849-32CCB66406E1Q36990362-667685C2-91D1-46B2-BA69-B3593D4D1CEFQ37718676-4E10D496-CFB3-44E0-AEDD-7ED963594F74Q38374581-5D05E515-1A1B-457D-B161-527D4EA4C211Q38396913-1CCC1BD9-9A79-46BD-B7F9-013D3ADB5432Q39714017-56E0FF86-F5CF-4314-959A-21DE3A87890EQ47109230-CC6B0824-5062-43C7-BF56-3F54D15899CCQ47147559-7F06A2ED-B6B3-4C85-B8CA-347A76841699Q47956183-6E26C871-08B7-446D-9F4B-323071FFE91CQ96431694-8A255EB7-9335-4637-BF4E-95DF2E6B2D34
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Darren Barton
@ast
Darren Barton
@en
Darren Barton
@es
Darren Barton
@nl
type
label
Darren Barton
@ast
Darren Barton
@en
Darren Barton
@es
Darren Barton
@nl
prefLabel
Darren Barton
@ast
Darren Barton
@en
Darren Barton
@es
Darren Barton
@nl
P106
P31
P496
0000-0003-0106-5861